<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876420</url>
  </required_header>
  <id_info>
    <org_study_id>MDT10093773DOC</org_study_id>
    <nct_id>NCT01876420</nct_id>
  </id_info>
  <brief_title>The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study</brief_title>
  <official_title>The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and clinical performance of the CoreValve™ Evolut R™ System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives are to assess the safety and clinical performance of the CoreValve™
      Evolut R™ System in patients with severe symptomatic aortic stenosis who are considered at
      high through extreme risk for surgical aortic valve replacement. These objectives will be
      accomplished by a prospective clinical study involving up to 60 implanted subjects among up
      to six study centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality Rate at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>The All-cause mortality rate at 30 days per the VARC II recommendation of clinical endpoints for TAVI. More specifically:
Cardiovascular mortality (Any of the following criteria)
Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause Non-cardiovascular mortality
Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke Rate (Disabling and Non-disabling) at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>The Stroke rate (disabling and non-disabling) at 30 days per the VARC II definitions. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Stroke may be classified as ischaemic or haemorrhagic with appropriate subdefinitions. Ischaemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Haemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage. A stroke may be classified as 'undetermined' if there is insufficient information to allow the categorization as ischaemic or haemorrhagic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Success Rate at 24 Hours to Seven Days</measure>
    <time_frame>24 hours to seven days</time_frame>
    <description>Device success rate at 24 hours to seven days, defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity &lt; 3 m/sec), AND absence of moderate or severe prosthetic valve regurgitation.
The percentage of subjects with no more than mild aortic regurgitation at early post procedure echocardiogram (24 hours through seven days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC II Combined Safety Endpoint at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>The VARC II Combined Safety Endpoint at 30 days includes the following components: All-Cause Mortality, All Stroke, Life Threatening or Disabling Bleeding, Acute Kidney Injury: Stage 2 or 3, Coronary Artery Obstruction, Major Vascular Complication, and Valve-Related Dysfunction Requiring Repeat Procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rates of the Individual Components of the VARC II Composite Safety Endpoint at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>The Individual components of the VARC II composite safety endpoint at 30 days per the Kaplan Meier Event Rate (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Mean Gradient</measure>
    <time_frame>30 days</time_frame>
    <description>The hemodynamic performance will be measured by the Mean Prosthetic Valve Gradient for 59 subjects, measured with the Doppler echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - • Effective Orifice Area (EOA)</measure>
    <time_frame>30 days</time_frame>
    <description>Effective orifice area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Total Aortic Regurgitation (Transvalvular &amp; Paravalvular)</measure>
    <time_frame>30 days</time_frame>
    <description>Degree of Total prosthetic valve regurgitation (transvalvular &amp; paravalvular)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resheath or Recapture Success Rate (When Attempted), Where Successful Recapture is Defined as Evolut R™ TAV (Including the Frame) is Fully Resheathed Into the Capsule of the Delivery Catheter, as Verified by Fluoroscopy.</measure>
    <time_frame>Day 1</time_frame>
    <description>Resheath or Recapture success rate (when attempted), where successful recapture is defined as Evolut R™ TAV (including the frame) is fully resheathed into the capsule of the delivery catheter, as verified by fluoroscopy. Resheathing or recapturing of the TAV was attempted on 15 subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>The CoreValve™ Evolut R TAV™ system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 &amp; 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The CoreValve™ Evolut R TAV™ system</intervention_name>
    <description>CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 &amp; 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System</description>
    <arm_group_label>The CoreValve™ Evolut R TAV™ system</arm_group_label>
    <other_name>CoreValve™ EvolutR™ Transcatheter Ao Valve</other_name>
    <other_name>EnveoR™ Delivery Catheter System w/ Enveo InLine™ Sheath</other_name>
    <other_name>EnVeoR™ Loding System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe aortic stenosis, defined as aortic valve area of &lt; 1.0 cm2 (or aortic valve
             area index of &lt; 0.6 cm2/m2) by the continuity equation, AND mean gradient &gt; 40 mmHg or
             maximal aortic valve velocity &gt; 4.0 m/sec by resting echocardiogram.

          2. Estimated 30 day mortality risk of &gt; 15% by study center Heart Team assessment,33 OR
             at least two cardiovascular surgeons from the study center deny surgery because of
             prohibitive operative risk, estimated to be a combined &gt;50% risk of irreversible
             mortality or morbidity.

          3. Symptoms of aortic stenosis, and NYHA Functional Class II or greater.

          4. The subject meets the legal minimum age to provide informed consent based on local
             regulatory requirements, and has provided written informed consent as approved by the
             EC/IRB of the respective clinical site.

          5. The subject and the treating physician agree that the subject will return for all
             required post-procedure follow-up visits.

             Exclusion Criteria:

             Clinical exclusion criteria:

          6. Subject has been offered SAVR but has declined.

          7. Any condition considered a contraindication for placement of a bioprosthetic valve
             (e.g. subject is indicated for mechanical prosthetic valve).

          8. Known hypersensitivity or contraindication to Nitinol.

          9. Blood dyscrasias as defined: leukopenia (WBC &lt;1000 mm3), thrombocytopenia (platelet
             count &lt;50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or
             hypercoagulable states.

         10. Untreated clinically significant coronary artery disease requiring revascularization.

         11. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF)
             &lt;20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.

         12. End stage renal disease requiring chronic dialysis of creatinine clearance &lt; 20
             cc/min.

         13. Ongoing sepsis, including active endocarditis.

         14. Any condition considered a contraindication to extracorporeal assistance.

         15. Any percutaneous coronary or peripheral interventional procedure with a bare metal
             stent performed within 30 days prior to Heart Team assessment, or within six months
             prior to Heart Team assessment for procedures with a drug eluting stents.

         16. Symptomatic carotid or vertebral artery disease or successful treatment of carotid
             stenosis within eight weeks of Heart Team Assessment .

         17. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
             mechanical hemodynamic support.

         18. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or
             transient ischemic attack (TIA).

         19. Gastrointestinal (GI) bleeding that would preclude anticoagulation.

         20. Subject refuses a blood transfusion.

         21. Severe dementia (resulting in either inability to provide informed consent for the
             study/procedure, prevents independent lifestyle outside of a chronic care facility, or
             will fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits).

         22. Estimated life expectancy of less than 12 months due to associated non-cardiac
             co-morbid conditions.

         23. Other medical, social, or psychological conditions that in the opinion of the
             Investigator precludes the subject from appropriate consent or adherence to the
             protocol required follow-ups exams.

         24. Currently participating in an investigational drug or another device study (excluding
             registries).

         25. Evidence of an acute myocardial infarction ≤30 days before the index procedure.

         26. Need for emergency surgery for any reason.

         27. Liver failure (Child-C).

         28. Subject is pregnant or breast feeding.

             Anatomical exclusion criteria:

         29. Pre-existing prosthetic heart valve in any position.

         30. Mixed aortic valve disease (aortic stenosis with moderate or severe aortic
             regurgitation).

         31. Severe mitral regurgitation.

         32. Severe tricuspid regurgitation.

         33. Moderate or severe mitral stenosis.

         34. Hypertrophic obstructive cardiomyopathy.

         35. Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac
             mass thrombus or vegetation.

         36. Congenital bicuspid or unicuspid valve verified by echocardiography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Vang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director Clinical Research Structural Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>August 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2018</results_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Implanted Subjects</title>
          <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed 30 day visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All implanted subjects</population>
      <group_list>
        <group group_id="B1">
          <title>The CoreValve™ Evolut R TAV™ System</title>
          <description>CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 &amp; 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
The CoreValve™ Evolut R TAV™ system: CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 &amp; 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I Subject with cardiac disease but without resulting limitations of physical activity. Class II Subjects with cardiac disease resulting in slight limitation of physical activity. Class III Subjects with cardiac disease resulting in marked limitation of physical activity. Class IV Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS Score</title>
          <description>The Society of Thoracic Surgeons (STS) risk model predicts the risk of operative mortality and morbidity after adult cardiac surgery on the basis of patient demographic and clinical variables. After information has been entered on a given case, the online STS risk calculator provides a risk percentage for each of the outcomes. The risk percentage estimates the chance of a specific outcome for a patient with the indicated risk factors. A higher score indicates a higher risk. A lower score indicates a lower risk.</description>
          <units>percent of risk for cardiac surgery</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Logistic EuroScore</title>
          <description>The European System for Cardiac Operative Risk Evaluation (EuroSCORE) is a method of calculating predicted operative mortality for patients undergoing cardiac surgery. If a risk factor is present, a weight/number is assigned. The weights are added to give an approximate percent of predicted mortality. A higher score indicates a higher risk. A lower score indicates a lower risk.</description>
          <units>percent risk for cardiac surgery</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA)</title>
          <units>m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality Rate at 30 Days</title>
        <description>The All-cause mortality rate at 30 days per the VARC II recommendation of clinical endpoints for TAVI. More specifically:
Cardiovascular mortality (Any of the following criteria)
Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause Non-cardiovascular mortality
Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide)</description>
        <time_frame>30 days</time_frame>
        <population>All implanted subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality Rate at 30 Days</title>
          <description>The All-cause mortality rate at 30 days per the VARC II recommendation of clinical endpoints for TAVI. More specifically:
Cardiovascular mortality (Any of the following criteria)
Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure
All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause Non-cardiovascular mortality
Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide)</description>
          <population>All implanted subjects at 30 days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroke Rate (Disabling and Non-disabling) at 30 Days</title>
        <description>The Stroke rate (disabling and non-disabling) at 30 days per the VARC II definitions. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Stroke may be classified as ischaemic or haemorrhagic with appropriate subdefinitions. Ischaemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Haemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage. A stroke may be classified as 'undetermined' if there is insufficient information to allow the categorization as ischaemic or haemorrhagic.</description>
        <time_frame>30 days</time_frame>
        <population>All implanted subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke Rate (Disabling and Non-disabling) at 30 Days</title>
          <description>The Stroke rate (disabling and non-disabling) at 30 days per the VARC II definitions. Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Stroke may be classified as ischaemic or haemorrhagic with appropriate subdefinitions. Ischaemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Haemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage. A stroke may be classified as 'undetermined' if there is insufficient information to allow the categorization as ischaemic or haemorrhagic.</description>
          <population>All implanted subjects at 30 days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Device Success Rate at 24 Hours to Seven Days</title>
        <description>Device success rate at 24 hours to seven days, defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity &lt; 3 m/sec), AND absence of moderate or severe prosthetic valve regurgitation.
The percentage of subjects with no more than mild aortic regurgitation at early post procedure echocardiogram (24 hours through seven days).</description>
        <time_frame>24 hours to seven days</time_frame>
        <population>All implanted subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success Rate at 24 Hours to Seven Days</title>
          <description>Device success rate at 24 hours to seven days, defined as:
Absence of procedural mortality, AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND
Intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity &lt; 3 m/sec), AND absence of moderate or severe prosthetic valve regurgitation.
The percentage of subjects with no more than mild aortic regurgitation at early post procedure echocardiogram (24 hours through seven days).</description>
          <population>All implanted subjects at 30 days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Device Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of Procedural Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correct Positioning of Single Valve</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intended Performance of Prosthetic Heart Valve</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of Patient Prosthesis Mismatch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Gradient &lt; 20mmHg or Peak Velocity &lt; 3m/sec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of Mod. or Severe Prosthetic Regurgitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VARC II Combined Safety Endpoint at 30 Days</title>
        <description>The VARC II Combined Safety Endpoint at 30 days includes the following components: All-Cause Mortality, All Stroke, Life Threatening or Disabling Bleeding, Acute Kidney Injury: Stage 2 or 3, Coronary Artery Obstruction, Major Vascular Complication, and Valve-Related Dysfunction Requiring Repeat Procedure.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>VARC II Combined Safety Endpoint at 30 Days</title>
          <description>The VARC II Combined Safety Endpoint at 30 days includes the following components: All-Cause Mortality, All Stroke, Life Threatening or Disabling Bleeding, Acute Kidney Injury: Stage 2 or 3, Coronary Artery Obstruction, Major Vascular Complication, and Valve-Related Dysfunction Requiring Repeat Procedure.</description>
          <units>percentage probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rates of the Individual Components of the VARC II Composite Safety Endpoint at 30 Days</title>
        <description>The Individual components of the VARC II composite safety endpoint at 30 days per the Kaplan Meier Event Rate (%).</description>
        <time_frame>30 days</time_frame>
        <population>The number of subjects analyzed at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rates of the Individual Components of the VARC II Composite Safety Endpoint at 30 Days</title>
          <description>The Individual components of the VARC II composite safety endpoint at 30 days per the Kaplan Meier Event Rate (%).</description>
          <population>The number of subjects analyzed at 30 days.</population>
          <units>percentage of probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Combined Safety Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life Threatening or Disabling Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Kidney Injury: Stage 2 or 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Obstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Vascular Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve-Related Dysfunct. Requiring Repeat Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Mean Gradient</title>
        <description>The hemodynamic performance will be measured by the Mean Prosthetic Valve Gradient for 59 subjects, measured with the Doppler echocardiography.</description>
        <time_frame>30 days</time_frame>
        <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, only 57 of the echos were able to measure the Mean Gradient for those subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Mean Gradient</title>
          <description>The hemodynamic performance will be measured by the Mean Prosthetic Valve Gradient for 59 subjects, measured with the Doppler echocardiography.</description>
          <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, only 57 of the echos were able to measure the Mean Gradient for those subjects.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - • Effective Orifice Area (EOA)</title>
        <description>Effective orifice area</description>
        <time_frame>30 days</time_frame>
        <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, only 54 of the echos were able to measure the EOA for those subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - • Effective Orifice Area (EOA)</title>
          <description>Effective orifice area</description>
          <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, only 54 of the echos were able to measure the EOA for those subjects.</population>
          <units>cm²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Total Aortic Regurgitation (Transvalvular &amp; Paravalvular)</title>
        <description>Degree of Total prosthetic valve regurgitation (transvalvular &amp; paravalvular)</description>
        <time_frame>30 days</time_frame>
        <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, and 58 of the echos were able to measure the Total Aortic Regurgitation for those subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics at 30 Days by Doppler Echocardiography - Total Aortic Regurgitation (Transvalvular &amp; Paravalvular)</title>
          <description>Degree of Total prosthetic valve regurgitation (transvalvular &amp; paravalvular)</description>
          <population>All implanted subjects who had echos at the 30 day visit, which were 58 subjects, and 58 of the echos were able to measure the Total Aortic Regurgitation for those subjects.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resheath or Recapture Success Rate (When Attempted), Where Successful Recapture is Defined as Evolut R™ TAV (Including the Frame) is Fully Resheathed Into the Capsule of the Delivery Catheter, as Verified by Fluoroscopy.</title>
        <description>Resheath or Recapture success rate (when attempted), where successful recapture is defined as Evolut R™ TAV (including the frame) is fully resheathed into the capsule of the delivery catheter, as verified by fluoroscopy. Resheathing or recapturing of the TAV was attempted on 15 subjects.</description>
        <time_frame>Day 1</time_frame>
        <population>Subjects who had either a resheath or recapture attempt at implant and the success rate for each resheathing, or recapturing attempts of the valve at the implant.</population>
        <group_list>
          <group group_id="O1">
            <title>All Implanted Subjects</title>
            <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
          </group>
        </group_list>
        <measure>
          <title>Resheath or Recapture Success Rate (When Attempted), Where Successful Recapture is Defined as Evolut R™ TAV (Including the Frame) is Fully Resheathed Into the Capsule of the Delivery Catheter, as Verified by Fluoroscopy.</title>
          <description>Resheath or Recapture success rate (when attempted), where successful recapture is defined as Evolut R™ TAV (including the frame) is fully resheathed into the capsule of the delivery catheter, as verified by fluoroscopy. Resheathing or recapturing of the TAV was attempted on 15 subjects.</description>
          <population>Subjects who had either a resheath or recapture attempt at implant and the success rate for each resheathing, or recapturing attempts of the valve at the implant.</population>
          <units>percentage of successful attempts</units>
          <param>Number</param>
          <units_analyzed>Research recapture attempts</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Research recapture attempts</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success rate for Resheath or Recapture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success rate for Resheath</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success rate for Recapture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days.</time_frame>
      <desc>All SAE should be reported as soon as possible, not later than within ten days of knowledge of the event. All other adverse events should be reported as soon as possible, not later than within three weeks.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Attempted Implanted Subjects</title>
          <description>Sixty subjects were implanted with the Evolut R valve from six centers in Australia, the United Kingdom, and New Zealand.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Conduction Disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Supraventricular arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischemic Coronary Artery Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Decreased BP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestianl Ulcers and Perforation, Site Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Signs and Symptoms Nec</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract And Lung Infections</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure and Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Ascribed to Specific Agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias Nec</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenias</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Conduction Disorders</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac Disorders Nec</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Heart Failure Nec</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischemic Coronary Artery Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rate and Rhythm Disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrythmias</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aortic Valvular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ventricular Arrythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Atonic And Hypomobility</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Atonic And HypomobilitySigns and Symptoms Nec</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inflammations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Complication Associated with Device Nec</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections Nec</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Non-site specific Injuries Nec</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-site specific Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>General Nutrition Disorders</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headach Nec</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neurological Signs And Symptoms Nec</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressive Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure and Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary Abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal Disorder Nec</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing And Associated Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax And Pleural Effusions</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis And Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Subcutaneous Tissue Ulcerations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin injuries And Mechanical Dermatoses</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Hypotensive Disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Terry Noel</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-526-0309</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

